Engineering Better Molecules Using Artificial Intelligence Announcing our $130M Series BRead AnnouncementAnnouncing our $130M Series BRead AnnouncementAnnouncing our $130M Series BRead AnnouncementAnnouncing our $130M Series BRead AnnouncementAnnouncing our $130M Series BRead Announcement Engineeringbetter molecules usingartificial intelligenceDrug-like antibody design against challenging targets with atomic precisionWith Chai-2, we’re moving de novo antibody design past binding and closer than ever to real therapeutics.Read AnnouncementGet Access© 2026 All rights reserved.Contact UsTerms of ServicePrivacy Policy